Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 3/20 | 0.39 |
| ▸ | AKT2 | P31751 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428251 | 1.00 | FYN (0.40) | FYNAKT1AKT2BRAFMEN1 | |
| SCHEMBL1429276 | 0.78 | RAF1 (0.45) | AKT1AKT2HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL1428565 | 0.76 | PTGS2 (0.65) | AKT1AKT2BRAFPTGS2PTGS1 | |
| SCHEMBL15730061 | 0.71 | ALDH1A1 (0.39) | AKT1AKT2MEN1HPGDKMT2A | |
| SCHEMBL18136568 | 0.71 | MAPT (0.50) | MEN1USP2HPGDMAPK1KMT2A | |
| SCHEMBL16981100 | 0.70 | KMT2A (0.63) | AKT1AKT2BRAFMEN1HPGD | |
| Hydrochloric Acid SCHEMBL18128839 | 0.70 | ALDH1A1 (0.38) | AKT1AKT2MEN1HPGDKMT2A | |
| SCHEMBL18203558 | 0.69 | AKT1 (0.56) | AKT1AKT2HPGDSMN1; SMN2 | |
| SCHEMBL3245505 | 0.66 | PTGS2 (0.64) | PTGS2PTGS1 | |
| Biphenyl SCHEMBL27280595 | 0.65 | TSHR (0.68) | FYNBRAFMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387204-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-8592591-B2 | Fused bicyclic imidazoles | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2176259-B1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2176259-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-2062893-A1 | Fused imidazoles for cancer treatment | Bayer Schering Pharma AG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2009021990-A1 | FUSED IMIDAZOLES FOR CANCER TREATMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088110-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | FYN 130/4885AKT1 3/4885AKT2 2/4885 |
| US-20090156604-A1 | FUSED BICYCLIC IMIDAZOLES | MTOR, AKT2, AKT1 | FYN 130/4885AKT1 3/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.